Market revenue in 2023 | USD 63.2 million |
Market revenue in 2030 | USD 140.3 million |
Growth rate | 12.1% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.94% in 2023. Horizon Databook has segmented the Brazil hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
In LATAM, Brazil has the largest population. Brazil has been experiencing economic growth due to recent financial and political stability in the region. Healthcare expenditure in Brazil is around USD 190 billion, which is among the highest healthcare expenditures in the world. Its biopharmaceutical industry is doing better than other industries in the country, owing to increasing government investments to improve healthcare.
However, a lack of awareness of their severe implications and limited attention in public policy limited the rate of diagnosis, thereby hindering the market growth. Moreover, the market growth can be attributed to supportive government initiatives, such as Sistema Único de Saúde (SUS) and the public health system, which cover health insurance for all citizens in Brazil.
There are several steps taken in the country to attain proper information regarding the prevalence of the condition. For instance, in 2019, the Ministry of Health of Brazil, in collaboration with the National Council for Scientific and Technological Development (CNPq), announced & issued a call for research to acquire epidemiological information on rare diseases in Brazil.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Brazil hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account